{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-171489","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2022-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.521786+00:00","generated_at":"2026-06-25T02:45:52.591464+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cogent announces positive initial Phase 2 APEX data for bezuclastinib in advanced systemic mastocytosis","bullets":["All 11 patients achieved ≥50% serum tryptase reduction; median reduction 89%.","All 8 evaluable patients had ≥50% bone marrow mast cell reduction; six cleared aggregates.","No periorbital/peripheral edema, cognitive effects, or intracranial bleeding reported.","Two prior avapritinib patients showed similar benefit; all remained on study at cutoff.","Company to accelerate timelines; next APEX update by end of 2022; SUMMIT data in H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-171489","json":"https://secwatch.observer/filing/0001193125-22-171489.json","markdown":"https://secwatch.observer/filing/0001193125-22-171489.md","text":"https://secwatch.observer/filing/0001193125-22-171489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312522171489/0001193125-22-171489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312522171489/d330856d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:45:52.591464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}